Last Updated : March 21, 2024
Details
Generic Name:
risperidone
Project Status:
Suspended
Therapeutic Area:
Schizophrenia, adults
Manufacturer:
Teva Canada Innovation
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0811-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
For the treatment of schizophrenia in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 30-Aug-23 |
|---|---|
| Call for patient/clinician input closed | 24-Oct-23 |
| Clarification: - No patient input submission received | |
| Submission received | 13-Oct-23 |
| Submission accepted | 27-Oct-23 |
| Review initiated | 30-Oct-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 01-Feb-24 |
| Deadline for sponsors comments | 12-Feb-24 |
| Clarification: - Submission temporarily suspended | |
| CADTH review report(s) and responses to comments provided to sponsor | - |
| Expert committee meeting (initial) | - |
| Draft recommendation issued to sponsor | - |
| Draft recommendation posted for stakeholder feedback | - |
| End of feedback period | - |
Last Updated : March 21, 2024